By Turna Ray

HYATTSVILLE, Md. (GenomeWeb Daily News) – During the first day of a two-day meeting held here this week to discuss the US Food and Drug Administration's regulatory strategy for laboratory-developed tests, agency officials said that all options are on the table and "nothing is set in stone."

However, comments from one high-ranking agency official provided a glimpse of the ideas in play with regard to its risk-based regulation of LDTs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.